Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Collaboration supports multiple discovery efforts, including vaccines
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The vaccine is under FDA review
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies
Subscribe To Our Newsletter & Stay Updated
